CDH13 Linked to Lowered Levels of Adiponectin

Risk of metabolic syndrome, type 2 diabetes in men, ischemic stroke all linked to SNP in CDH13

WEDNESDAY, July 27 (HealthDay News) -- A single nucleotide polymorphism (SNP) in the T-cadherin (CDH13) gene is associated with lowered adiponectin levels and an increased risk of cardiometabolic diseases, according to a study published online July 19 in Diabetes.

Chia-Min Chung, from the Institute of Biomedical Sciences in Taipei, Taiwan, and colleagues conducted a genome-wide association study to identify genetic variants modulating plasma adiponectin levels and investigate the association of adiponectin-related metabolic traits and cardiovascular diseases with these variants. A total of 382 young-onset-hypertensive (YOH) subjects were genotyped using Illumina HumanHap550 SNP chips to identify quantitative trait loci associated with high molecular weight forms of adiponectin levels. The SNP variants responsible for lower adiponectin levels were then confirmed in another 559 YOH subjects. An independent community-based prospective cohort, from the Cardiovascular Disease Risk Factors Two-township Study (CVDFACTS), was used to evaluate the association of these SNP variants with the risk of metabolic syndrome, type 2 diabetes mellitus (T2DM), and ischemic stroke.

The investigators observed SNP rs4783244 in intron 1 of CDH13 to be significantly associated with adiponectin levels in the first stage. The association between rs4783244 and plasma adiponectin levels was confirmed in the second group of YOH individuals. In the CVDFACTS cohort, a significant association was observed between this SNP and the risk of metabolic syndrome (odds ratio [OR], 1.42), T2DM in men (OR, 3.25), and ischemic stroke (OR, 2.13).

"CDH13 has an influence not only on adiponectin levels in the blood but also on the risk of metabolic syndrome, T2DM, and ischemic stroke," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing